Science & Technology

Although there is broad agreement between the two major parties on the desirability of technology leadership, significant sources of tension—and confusion—persist. By examining the political dynamics that led to the enactment of the CHIPS and Science Act, Constanza M. Vidal Bustamante and Douglass Vijay Calidas probe these tensions and seek to assess their likely impact on the federal technology strategy in the coming years.

Stephen Walt analyzes the priority that the United States should place on competing with China by asking and answering five questions.

The European Union is planning to adopt semiconductor export controls, restrictions on outbound investment in China, and new rules to reduce the European market share of Chinese renewables. This strategy brings Brussels' into closer alignment with Washington and is likely to increase tensions with Beijing significantly.

U.S. export controls on China’s semiconductor industry are just the opening salvos in a series of unprecedented export controls on China planned by the Biden administration. After controls on semiconductors, the Commerce Department is moving on to the next emerging technology it worries China could weaponize—quantum computing.

Establishing norms for state behavior in cyberspace is critical to building a more stable, secure, and safe cyberspace. Norms are defined as “a collective expectation for the proper behavior of actors with a given identity,” and declare what behavior is considered appropriate and when lines have been crossed. Cyberspace is in dire need of such collective expectations. However, despite efforts by the international community and individual states to set boundaries and craft agreements, clear and established cyber norms for state behavior remain elusive. As early as 2005, the UN Group of Governmental Experts (GGE) and UN Open-Ended Working Group (OEWG) both aimed to create shared “rules of the road,” but fundamental disagreements between states and a lack of accountability and enforcement mechanisms have prevented these initiatives from substantively implementing cyber norms. As a result, the international community and individual states are left with no accountability mechanisms or safeguards to protect civilians and critical infrastructure from bad actors in cyberspace.

Joseph Nye writes: From an American perspective, it is just as dangerous to underestimate Chinese power as it is to overestimate it. While hysteria creates fear, discounting China's recent progress and future ambitions could lead the United States to squander its own long-term advantages.

In recent years, there has been an increased focus on finding treatments for neurodegenerative diseases such as Alzheimer's and Parkinson's, as the prevalence of these diseases continues to rise globally. This blog aims to provide an overview of the sources and trends of funding for neurodegenerative disease research, with a particular focus on comparing funding for these diseases with that of other classes of diseases. By examining historical funding trends and the current sources of funding, we seek to shed light on the current state of the funding ecosystem for neurodegenerative disease research. We will also explore how funding is allocated across different types of neurodegenerative diseases and discuss potential bottlenecks in the funding process that may be hindering progress in the development of therapies.

*This blog is part of a series titled TAPP for Neurodegenerative Diseases Drug Discovery: Mapping the ecosystem

Neurodegenerative diseases (NDDs) are a class of disorders that cause the progressive loss of structure or function of neurons, leading to declines in cognitive and physical abilities. Drug discovery and development for these diseases is a complex, multi-stakeholder process involving a variety of entities across the United States, including government agencies, businesses, research institutions, academic institutions, and non-profit organizations. These stakeholders interact with each other at various stages of the non-linear cycle of drug development, which typically involves a range of activities including pre-clinical research, clinical trials, regulatory approval, and commercialization.

Given the complexity of this process and the challenges involved in developing effective treatments for NDDs, it is important to better understand the role of different stakeholders and the potential barriers they face. This blog aims to provide a deeper examination of the various stakeholders involved in NDD drug discovery and development, and to offer an initial hypothesis on key challenges that may be contributing to the lack of disease-altering therapies for these conditions.

*This blog is part of a series titled TAPP for Neurodegenerative Diseases Drug Discovery: Mapping the ecosystem

Neurodegenerative diseases (NDD) such as Alzheimer’s, Parkinson’s, and ALS represent a global health crisis affecting more than nine million people in the United States alone. NDDs are caused by progressive loss of central nervous system neurons - currently, there is no cure to reverse this loss. The only approved therapies are palliative or mildly reduce some symptoms. In this blog, the author introduces ways technology and public policy can improve the drug discover process to "cure the uncureable" - setting the stage for his larger research project this academic year.

Ivan Arreguin-Toft analyzes the West's information technology asymmetry of capability, which has given way to asymmetry of vulnerability. While democracies worldwide remain threatened, they also contain the means to restore themselves.